Presentations -
-
ヒト急性白血病モデルマウスにおける211At-CD82の体内動態
第61回日本核医学会学術総会 2021.11
-
Evaluation of acute radiotoxicity profile of alpha-particle-emitting meta-211At-astato-benzylguanidine (211At-MABG) in normal BALB/c mice
SNMMI2021 Annual Meeting 2021.6
-
Evaluation of effect of Ninjin'yoeito on regional brain glucose metabolism by 18F-FDG autoradiography with insulin loading in superaged mice
SNMMI2021 Annual Meeting 2021.6
-
Effect of the targeted alpha therapy using mutant streptavidin bisiminobiotin pre-targeting system in a human gastric cancer cell xenograft
-
Synthesis of bis-iminobiotin derivatives and labeling with Astatine-211
-
Biodistribution studies of 211At labeled bis-iminobiotins for pretargeting radionuclide therapy
-
Optimization for pre-targeted radionuclide therapy using 211At labeled bis-iminobiotin
-
Similarities and differences of dosimetry between meta-[211At]astatobenzylguanidine (211At-MABG) and meta-[123I]iodobenzylguanidine (123I-MIBG) as companion diagnostic drug
-
Acute dose response of hemato-toxicity of 211At-MABG in normal mice
-
Effects and safety of alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG) comparison with 131I-meta-iodobenzylguanidine (131I-MIBG) in a pheochromocytoma mouse model
-
Preclinical Evaluation of Radiotoxicity of 211At-MABG in normal mice.
-
Biodistribution and dosimetry studies for the optimization of pre-targeted radionuclide therapy using 211At-labeled modified biotin.
EANM'20 - Annual Congress of the European Association of Nuclear Medicine
-
Evaluation of therapeutic effect of the targeted alpha therapy using Cupid-211At-labeled Psyche-B pretargeting system in a human gastric cancer cell xenograft.
EANM'20 - Annual Congress of the European Association of Nuclear Medicine
-
Search for the optimal bis-iminobiotin for the pretargeting strategy using a mutated low immunogenic streptavidin.
EANM'20 - Annual Congress of the European Association of Nuclear Medicine
-
Comparative evaluation of radiation dosimetry between meta-[211At]astatobenzylguanidine (211At-MABG) and meta-[123I]iodobenzylguanidine (123I-MIBG)
-
α放射体211At標識イミノビオチンの作成と安定性評価
日本放射線影響学会第63回大会
-
Differences and similarities in biodistribution, pharmacokinetics and metabolites of 211At-MABG versus 123I-MIBG in normal mice.
Society of Nuclear Medicine Annual Meeting (SNMMI 2020)
-
Effects and safety of alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG) compared with 131I-meta-iodobenzylguanidine (131I-MIBG) on tumor growth suppression in a pheochromocytoma mouse model.
Society of Nuclear Medicine Annual Meeting (SNMMI 2020)
-
Feasibility of cancer stem cells-targeted radioimmunotherapy for acute myelogenous leukemia with 211At-CXCR4 monoclonal antibody.
-
Development of a low immunogenic mutated streptavidin pretargeting strategy with 211At labeled modified biotin for advanced cancer treatment.
Society of Nuclear Medicine Annual Meeting (SNMMI 2020)